Novadaq Technologies Inc.TSX: NDQ

Novadaq to present at IBC Ocular Anti-angiogenesis Conference

· Issued by Novadaq Technologies Inc. via CNW
TORONTO, March 28 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, today announced a
corporate presentation to be given at the IBC Ocular Anti-angiogenesis
Conference on March 29, at the Hotel (at) MIT in Cambridge, Massachusetts.
Dr. Robert Devenyi, Ophthalmologist-in-Chief and Director of Retinal Services
for the University Health Network, and Professor of Ophthalmology and Vision
Sciences at the University of Toronto will conduct the presentation on
"Unlocking the Potential of Feeder Vessel Therapy in Macula Degeneration". His
presentation will outline the safety and efficacy of feeder vessel therapy and
some of the latest technology being used for diagnosis, treatment and
evaluation by Novadaq Technologies.

About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular, ophthalmic, and neurologic diseases and
conditions. Novadaq's SPY(R) Intra-operative Imaging System, commercially
available worldwide, enables cardiac surgeons to visually assess coronary
vasculature and bypass graft functionality during the course of open-heart
bypass surgery. Novadaq's ophthalmic product, the OPTTX(R) System, is aimed at
the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials. Novadaq's product for nerve visualization in prostate surgery,
LUNA(TM) is designed to enable surgeons to visualize nerve bundles during the
course of radical prostatectomy in order to reduce negative outcomes including
impotency. For more information, please visit the company's website at
www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases